Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.72 |
| ▸ | CTSS | P25774 | 11/20 | 0.60 |
| ▸ | CTSK | P43235 | 10/20 | 0.60 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261103 | 1.00 | PTPN1 (0.72) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6780479 | 0.91 | PTPN1 (0.85) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL8304409 | 0.85 | CTSS (0.55) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL1826757 | 0.84 | CTSS (0.69) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL2802961 | 0.84 | CTSS (0.69) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL10033679 | 0.84 | CTSS (0.69) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL5262564 | 0.84 | ITGA4 (0.56) | PTPN1CTSSCTSKKLK5ITGB1 | |
| SCHEMBL1828316 | 0.84 | ITGA4 (0.56) | PTPN1CTSSCTSKKLK5ITGB1 | |
| SCHEMBL6637197 | 0.84 | PTPN1 (0.54) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL539374 | 0.84 | CTSS (0.62) | PTPN1CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | PTPN1 3546/4885CTSS 3471/4885CTSK 3593/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | PTPN1 4408/4885CTSS 3694/4885CTSK 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.